Quest Diagnostics
DGX
969 hedge funds and large institutions have $17.5B invested in Quest Diagnostics in 2025 Q1 according to their latest regulatory filings, with 144 funds opening new positions, 317 increasing their positions, 337 reducing their positions, and 62 closing their positions.
132% more first-time investments, than exits
New positions opened: 144 | Existing positions closed: 62
17% more capital invested
Capital invested by funds: $15B → $17.5B (+$2.52B)
8% more funds holding
Funds holding: 897 → 969 (+72)
4.24% more ownership
Funds ownership: 89.04% → 93.27% (+4.2%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less repeat investments, than reductions
Existing positions increased: 317 | Existing positions reduced: 337
39% less call options, than puts
Call options by funds: $83.5M | Put options by funds: $136M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Boston Partners
Boston,
Massachusetts
|
+$377M |
| 2 |
JP Morgan Chase
New York
|
+$219M |
| 3 |
Nordea Investment Management
Stockholm,
Sweden
|
+$120M |
| 4 |
Neuberger Berman Group
New York
|
+$93.8M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$81.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$105M |
| 2 |
Aberdeen Group
Edinburgh,
United Kingdom
|
-$56.7M |
| 3 |
American Century Companies
Kansas City,
Missouri
|
-$51.4M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$51.4M |
| 5 |
Prudential Financial
Newark,
New Jersey
|
-$44.8M |
DGX Hedge Fund Activity: Q1 2025 in Review
969 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Quest Diagnostics (DGX) for Q1 2025, worth a combined $17.5B — up 17% from $15B a quarter earlier.
Buyers outnumbered sellers: 144 funds opened new DGX positions and 62 closed out — a net gain of 82 holders — while 317 added to existing stakes and 337 trimmed.
The largest buyer was Boston Partners, opening a new position worth an estimated $377M. The largest seller was Millennium Management, cutting an estimated $105M.
- 969 institutional investors held Quest Diagnostics (DGX) as of Q1 2025, up from 897 in Q4 2024.
- Funds reported $17.5B of Quest Diagnostics stock for Q1 2025, up 17% quarter-over-quarter.
- 144 funds opened new Quest Diagnostics positions in Q1 2025 and 62 closed out, a net change of +82 holders.
- The largest Quest Diagnostics buyer in Q1 2025 was Boston Partners, an estimated $377M added.
- The largest Quest Diagnostics seller in Q1 2025 was Millennium Management, an estimated $105M sold.
Based on aggregated 13F filings for Q1 2025.